GMP IPO Watch
ICICI Prudential Healthcare Fund
Direct Plan · Cumulative · ICICI Prudential Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +2.62% | +3.52% | 217 of 255 |
| 1M | +2.24% | +1.97% | 125 of 255 |
| 3M | -1.24% | -3.45% | 60 of 252 |
| 6M | +7.34% | +2.92% | 64 of 251 |
| YTD | +9.42% | +1.21% | 51 of 255 |
| 1Y | +7.32% | +1.11% | 55 of 232 |
| 2Y | +6.78% | +2.39% | 49 of 187 |
| 3Y | +22.62% | +12.36% | 9 of 142 |
| 5Y | +17.14% | +9.81% | 15 of 102 |
| 7Y | +24.16% | +14.27% | 6 of 84 |
| INCEPTION | +20.62% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.27% | +52.59% | -13.99% | 67% | 27% |
| 6M | +11.19% | +80.68% | -14.68% | 71% | 30% |
| 1Y | +24.97% | +94.27% | -12.32% | 82% | 38% |
| 2Y | +25.82% | +54.04% | -0.12% | 100% | 47% |
| 3Y | +24.23% | +31.59% | +14.68% | 100% | 49% |
| 5Y | +23.61% | +34.79% | +14.97% | 100% | 48% |
| 7Y | +23.51% | +25.81% | +21.29% | 100% | 49% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity98.90%
- Debt0.00%
- Cash1.10%
- Other0.00%
Market Cap Split
- Large Cap23.36%
- Mid Cap32.83%
- Small Cap42.72%
- Others1.09%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.41 | 41.94 |
| P/B | 4.14 | 6.29 |
| Price / Sales | 3.89 | 6.05 |
| Price / Cash Flow | 25.60 | 31.26 |
| Dividend Yield (%) | 0.69 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 11.49% | -0.82% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 9.73% | +1.47% |
| Cipla | Pharmaceuticals & Biotechnology | 5.79% | +0.03% |
| Biocon | Pharmaceuticals & Biotechnology | 5.33% | +0.65% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 5.04% | -0.17% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.81% | -0.06% |
| Medplus Health Services | Retailing | 4.31% | +0.16% |
| TREPS | Reverse Repo / TREPS | 4.25% | — |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 4.06% | -0.02% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 3.78% | -1.05% |
| Syngene International | Equity | 3.50% | +0.21% |
| Dr. Agarwal's Health Care | Equity | 2.66% | -0.13% |
| Max Healthcare Institute | Equity | 2.63% | +0.04% |
| Abbott | Pharmaceuticals & Biotechnology | 2.54% | +0.16% |
| Alembic Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.50% | +0.02% |
View all 42 holdings
| Pfizer | Pharmaceuticals & Biotechnology | 2.42% | +0.56% |
| Apollo Hospitals | Equity | 2.30% | — |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.97% | — |
| Akums Drugs & Pharma | Pharmaceuticals & Biotechnology | 1.91% | -0.08% |
| Lupin | Pharmaceuticals & Biotechnology | 1.88% | -0.08% |
| AstraZeneca Pharma | Pharmaceuticals & Biotechnology | 1.85% | -0.14% |
| Blue Jet Healthcare | Pharmaceuticals & Biotechnology | 1.83% | -0.10% |
| Indegene | Equity | 1.74% | -0.18% |
| Metropolis Healthcare | Equity | 1.65% | -0.09% |
| Rainbow Childrens Medicare | Equity | 1.29% | -0.07% |
| Fine Organic Industries | Chemicals & Petrochemicals | 1.21% | -0.01% |
| Thyrocare Technologies | Equity | 1.17% | -0.13% |
| Aarti Drugs | Pharmaceuticals & Biotechnology | 1.17% | +0.07% |
| Medi Assist Healthcare | Insurance | 1.06% | -0.07% |
| Alivus Life Sciences | Pharmaceuticals & Biotechnology | 0.97% | -0.24% |
| Hikal | Pharmaceuticals & Biotechnology | 0.95% | -0.10% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 0.93% | -0.04% |
| Manipal Health Enterprises | Equity | 0.87% | -0.05% |
| Entero Healthcare Solutions | Retailing | 0.74% | -0.49% |
| Laxmi Dental | Equity | 0.68% | +0.01% |
| FDC | Pharmaceuticals & Biotechnology | 0.66% | +0.04% |
| Windlas Biotech | Pharmaceuticals & Biotechnology | 0.57% | +0.00% |
| Indraprastha Medical Corporation | Equity | 0.47% | — |
| Indoco Remedies | Pharmaceuticals & Biotechnology | 0.43% | -0.15% |
| Natco Pharma | Pharmaceuticals & Biotechnology | 0.02% | — |
| Cash Margin - Derivatives | Net Current Assets | 0.01% | — |
| Net Current Assets | Net Current Assets | -3.16% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.56 | 16.32 | Low Volatility |
| 3Y | 13.82 | 16.10 | Low Volatility |
| 5Y | 13.27 | 15.67 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.03 | -0.32 | Above Average |
| 3Y | 1.01 | -0.45 | Above Average |
| 5Y | 0.73 | 0.29 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.90 | 0.19 | Above Average |
| 3Y | 2.32 | 1.14 | Above Average |
| 5Y | 1.88 | 0.96 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.93 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.97 | 0.96 | Poor Risk Adjusted Returns |
| 5Y | 0.93 | 0.95 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From ICICI Prudential Asset Management Company Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ICICI Prudential Strategic Metal and Energy Equity Fund of Fund
Direct Plan · IDCW
|
+54.73% | +34.44% | — | +28.69% |
| ICICI PRUDENTIAL SILVER ETF | +26.35% | +36.57% | — | +24.10% |
|
ICICI Prudential Silver ETF FOF
Direct Plan · IDCW
|
+25.48% | +35.58% | — | +24.36% |
|
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · IDCW
|
+22.53% | +22.50% | — | +21.44% |
|
ICICI Prudential Global Stable Equity Fund (FOF)
Direct Plan · Growth
|
+21.49% | +15.76% | +11.03% | +10.51% |
|
ICICI Prudential US Bluechip Equity Fund
Direct Plan · IDCW
|
+21.29% | +19.31% | +13.10% | +16.61% |
| ICICI Prudential Nifty Metal ETF | +19.46% | — | — | +16.41% |
|
ICICI Prudential Gold ETF FOF
Direct Plan · Growth
|
+17.38% | +30.99% | +23.18% | +10.56% |
| ICICI Prudential Gold ETF | +16.94% | +31.16% | +23.37% | +12.02% |
|
ICICI Prudential NASDAQ 100 Index Fund
Direct Plan · Growth
|
+15.77% | +28.57% | +17.30% | +18.04% |
About This Scheme
Investment Objective
To generate long term capital appreciation through investments made primarily in equity & equity related securities of companies forming part of Healthcare sector. However there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Stated Asset Allocation
• Equity & Equity related instruments of companies forming part of Healthcare Sector 80%-100% • Other Equity & Equity related instruments 0%-20% • Money market instruments, other liquid instruments^, Units of Overnight funds, Liquid funds and Money Market funds 0%-20%• Units issued by InVits 0%-10% ^Other liquid instruments shall include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by SEBI.
Exit Load
1% of the applicable NAV - If units purchased or switched in from another scheme of the Fund are redeemed or switched out within 15 days from the date of allotment NIL - If units purchased or switched in from another scheme of the Fund are redeemed or switched out after 15 days from the date of allotment (w.e.f. 1st Jan 2019)
Fund Managers
FM 1 - Dharmesh Kakkad, FM 2 - Sharmila D'silva
FM 1 - Primary, FM 2 - Manages Overseas Investments
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.